Article

CAR T-Cell Therapy Offers Hope in DLBCL

Author(s):

Peter Borchmann, M.D.

CAR-T cell therapy is generating excitement for the treatment of diffuse large B-cell lymphoma, according to an update from the JULIET trial.

Findings from the JULIET trial are generating hope and excitement for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, according to Peter Borchmann, M.D., professor at the University Hospital of Cologne in Germany.

The phase 2 trial is investigating the CAR-T cell therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory DLBCL. Borchmann explained that at the median follow-up of 14 months, the researchers are still seeing a high amount of patients who are responding to treatment. While longer observation is needed, he said that the findings from this study are generating hope that more patients with DLBCL can obtain and remain in remission.

Related Videos
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Image of a man wearing a black suit and tie.
Image of a man with white hair and a white goatee.
Image of a woman with brown wavy hair, wearing a navy blue top.
Image of a man wearing a suit with a red bowtie.
Related Content
Picture of Dr. Guillermo Garcia-Manero
September 18th 2024

Why Transfusion Independence Matters for Patients With MDS

Alex Biese
An expert explained the burden that red blood cell transfusions can place on patients with MDS.
Mike Peters in the hospital holding a black guitar and chemo pole
June 1st 2023

Mike Peters of The Alarm Faces Cancer With Rock Optimism on New Album

Alex Biese
‘Forwards,’ the new album by Mike Peters and the Alarm, was written while he was hospitalized for treatment of chronic lymphocyte leukemia and pneumonia.
Image of a man wearing a light blue polo shirt.
July 18th 2024

Radiation a Curative-Intent Option in NSCLC and Interstitial Lung Disease

Alex Biese
For some patients with early non-small cell lung cancer and lung scarring, stereotactic ablative radiotherapy may be a viable option, research has shown.
Dr. Dawn Mussallem in a bright yellow shirt and pink hat, both with breast cancer ribbons on it, showing off her medal at the finish line of The DONNA Foundaton marathon | Photo credit: The DONNA Foundation
May 18th 2023

Doctor, Cancer Survivor and Marathoner Goes the Distance for Her Patients: ‘Now I Can Just Give’

Alex Biese
Dr. Dawn Mussallem of the Mayo Clinic tells CURE®’s “Cancer Horizons” podcast about how surviving stage 4 non-Hodgkin’s lymphoma and being a heart transplant recipient helps her connect with her patients.
Image of a microscope up close.
July 3rd 2024

Antibody Testing May Decrease Infection Risk in Blood Cancer Survivors

Brielle Benyon
More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.
Dr. Rahul Banerjee in an interview with CURE
June 19th 2024

Double Stem Cell Transplant Feasible for Some With Multiple Myeloma

Alex Biese
One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma.